盘龙药业(002864) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 198,828,511.27, representing a 13.70% increase compared to CNY 174,868,139.36 in the same period last year[5] - Net profit attributable to shareholders was CNY 20,081,539.34, up 13.21% from CNY 17,738,938.74 year-on-year[5] - Total operating revenue for Q1 2022 was CNY 198,828,511.27, an increase of 13.71% compared to CNY 174,868,139.36 in Q1 2021[23] - Net profit for Q1 2022 reached CNY 20,311,464.87, representing a growth of 10.34% from CNY 18,406,264.02 in Q1 2021[24] - The company reported a total profit of CNY 23,491,843.47 for Q1 2022, an increase from CNY 21,836,219.91 in Q1 2021[24] Cash Flow - The net cash flow from operating activities surged by 777.18% to CNY 39,416,073.24, compared to CNY 4,493,507.22 in the previous year[5] - Cash flow from operating activities for Q1 2022 was CNY 39,416,073.24, significantly higher than CNY 4,493,507.22 in Q1 2021[26] - The net cash flow from investing activities was -¥19,593,205.50, compared to -¥17,669,998.29 in the previous year, indicating an increase in investment outflows[27] - The total cash inflow from financing activities reached ¥414,450,344.29, significantly up from ¥40,111,147.60 in the same period last year[27] - The net cash flow from financing activities was ¥365,916,650.78, compared to ¥27,745,231.01 in the previous year, showing a substantial increase[27] - The net increase in cash and cash equivalents for the period was ¥385,739,518.52, compared to ¥14,568,739.94 in the previous year[27] - The ending balance of cash and cash equivalents was ¥805,044,185.42, a significant rise from ¥396,571,276.41 at the end of the same period last year[27] Assets and Liabilities - Total assets increased by 28.23% to CNY 1,705,713,064.18 from CNY 1,330,174,616.17 at the end of the previous year[5] - The total assets of the company increased to RMB 1,705,713,064.18, up from RMB 1,330,174,616.17 at the beginning of the year, representing a growth of approximately 28.2%[19] - The company's total current assets reached RMB 1,318,128,895.02, compared to RMB 956,446,085.23 at the start of the year, indicating a growth of approximately 37.9%[20] - Total liabilities as of Q1 2022 amounted to CNY 828,362,824.84, compared to CNY 522,967,375.29 in the same period last year[23] - The total liabilities of the company were not explicitly stated, but the increase in current liabilities indicates a potential shift in financial strategy[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,029[12] - The company’s weighted average return on equity was 2.51%, slightly up from 2.45% in the previous year[5] - Total equity attributable to shareholders of the parent company was CNY 861,297,792.12, up from CNY 791,384,719.19 in Q1 2021[23] Research and Development - Research and development expenses rose by 23.66% to CNY 2,041,330.57, reflecting increased investment in R&D[11] Borrowings and Financing - The company experienced a 200.00% increase in short-term borrowings, totaling CNY 150,000,000.00, primarily due to increased bank loans[10] - Short-term borrowings increased to RMB 150,000,000.00 from RMB 50,000,000.00, reflecting a 200% rise[20] - The company issued convertible bonds totaling RMB 27,600,000.00, with 2,760,000 bonds issued at a face value of RMB 100.00 each, aimed at supporting strategic development[17] - The company plans to enhance its core competitiveness through strategic investments funded by the proceeds from the convertible bonds[17] - The company is focused on long-term high-quality growth, supported by the issuance of convertible bonds and strategic investments in its main products[17] Inventory and Receivables - Inventory levels increased to RMB 74,324,549.40 from RMB 66,765,198.12, showing a growth of approximately 11.6%[20] - Accounts receivable decreased slightly to RMB 350,821,704.95 from RMB 361,350,459.45, a decline of about 2.9%[19] Earnings Per Share - The company reported a basic earnings per share of CNY 0.2300, an increase of 11.11% from CNY 0.2070[5] - Earnings per share for Q1 2022 was CNY 0.2300, compared to CNY 0.2070 in Q1 2021, reflecting a 11.66% increase[24] Audit Information - The company did not conduct an audit for the first quarter report[28]